Kijimea

Synformulas is a leading German consumer healthcare company specializing in the development and commercialization of evidence-based medical products, primarily under the flagship brand Kijimea. The company focuses on gastrointestinal health, with its most prominent product, Kijimea IBS, utilizing a specific heat-inactivated bacterial strain to treat irritable bowel syndrome by adhering to the intestinal wall. Synformulas operates as a subsidiary of the FUTRUE Group and maintains a strong presence in European markets and the United States. Their portfolio includes medical devices and high-end supplements targeting digestive disorders and skin health through microbiome-based interventions.